The Pep Edit Newsletter

Cheat sheet

Status: Not FDA-approved Reviewed

BPC-157

One of the most discussed names in gut and recovery. Volume of conversation is not the same as volume of human trials.

The evidence rail

How to read this
  1. Mechanistic: reached
  2. Cell research: reached
  3. Animal research: reached
  4. Human observational: reached, limited data
  5. Human clinical trial: not reached
  6. Established clinical use: not reached
Evidence
Limited human dataRung 4 of 6, limited data. People were observed, surveyed, or followed, or given the peptide in a small study with no comparison group. Useful for patterns, silent on cause.
Status
Not FDA-approvedNot approved for use as a drug. Often sold as a research chemical.

Why people are talking about it

Recovery and biohacking feeds treat it as a near-universal healing peptide, the name itself means body protection compound, and FDA compounding restrictions have kept it in the headlines.

What has it been studied for?

  • Gut lining and injury models, mostly in animals
  • Recovery and inflammation conversations in humans, with much thinner clinical data

What we know

  • The preclinical literature is large
  • It has been named in compounding and committee news

What we don’t

  • Robust, replicated human clinical outcomes for the uses people talk about online

What is known about safety

  • The FDA lists it among compounding substances that may carry safety risks, citing possible immune reactions, impurities, and limited safety information for the proposed routes
  • Published human safety data is very small: an uncontrolled chart review of 16 people with knee pain, and a pilot of 2 people given it by IV
  • No serious side effects were reported in those pilots, but studies that small cannot rule out uncommon or long-term harm
  • Products sold online as research chemicals are not checked for identity, purity, or sterility

Bottom line

Volume of conversation is not volume of evidence.

Education only. Not medical advice. Not a protocol.

Sources

  1. Humans, 16 people, retrospective, no comparison groupIntra-articular injection of BPC 157 for multiple types of knee pain (opens in a new tab)Lee and Padgett, Alternative Therapies in Health and Medicine, 2021
  2. Humans, 2 people, safety onlySafety of intravenous infusion of BPC157 in humans: a pilot study (opens in a new tab)Lee and Burgess, Alternative Therapies in Health and Medicine, 2025
  3. Review of animal and human workRegeneration or risk? A narrative review of BPC-157 for musculoskeletal healing (opens in a new tab)McGuire and colleagues, Current Reviews in Musculoskeletal Medicine, 2025
  4. Regulator statementCertain bulk drug substances for use in compounding that may present significant safety risks (opens in a new tab)US Food and Drug Administration, current as of April 2026

We link to the paper, the trial registry, or the regulator, never to a seller. A study type in the label tells you who or what was actually studied.

Spotted an error or a newer study? Tell the editors. Corrections are noted on the page. Our standards.

Keep reading

  • KPV

    A fragment of alpha-MSH studied for inflammation and skin. Research so far is in cells and animals.

    Evidence: Animal research. Reached rung 3 of 6, Animal research.Not FDA-approved
    InflammationGut healthSkin + hair
    Inflammation

  • Larazotide

    One of the few names in this space with multiple human trials, studied around celiac and tight junctions.

    Evidence: Human clinical trials. Reached rung 5 of 6, Human clinical trial.Investigational
    Gut health
    Gut

  • ARA-290

    Studied in nerve pain and inflammation. Small placebo-controlled trials exist. Large ones do not.

    Evidence: Small controlled trials. Reached rung 5 of 6, Human clinical trial, with limited data.Not FDA-approved
    Nerve + painInflammation
    Nerve / Pain

Every new sheet, once a month.

One email a month. The study type named, every time.